Premium
New medication treatment options for bipolar disorders
Author(s) -
Ketter T. A.,
Wang P. W.,
Nowakowska C.,
Marsh W. K.
Publication year - 2004
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.2004.00410.x
Subject(s) - lamotrigine , quetiapine , bipolar disorder , olanzapine , topiramate , mania , psychiatry , ziprasidone , divalproex , medicine , aripiprazole , zonisamide , gabapentin , hypomania , psychology , lithium (medication) , schizophrenia (object oriented programming) , epilepsy , alternative medicine , pathology
Objective: To assess new treatment options for bipolar disorders. Method: Controlled studies of new treatments for bipolar disorders were identified by computerized searches and reviews of scientific meeting proceedings, and were compiled by drug category. Results: Two main categories of medications, newer anticonvulsants and newer antipsychotics, are yielding emerging new treatment options for bipolar disorders. Newer anticonvulsants have diverse psychotropic profiles, and although not generally effective for acute mania, may have utility for other aspects of bipolar disorders (e.g. lamotrigine for maintenance or acute bipolar depression), or for comorbid conditions (e.g. gabapentin for anxiety or pain, topiramate for obesity, bulimia, alcohol dependence, or migraine, and zonisamide for obesity). In contrast, newer antipsychotics generally appear effective for acute mania, and some may ultimately prove effective in acute depression (e.g. olanzapine combined with fluoxetine, quetiapine) and maintenance (e.g. olanzapine). Conclusion: Emerging research is yielding new treatment options for bipolar disorders and comorbid conditions.